Yun Dai Selected Research

7-hydroxystaurosporine (UCN 01)

5/2013	PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
2/2011	Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
3/2008	Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.
9/2007	MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
5/2007	Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
12/2006	Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
11/2005	Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth.
6/2005	The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
2/2005	Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
4/2004	Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yun Dai Research Topics

Disease

59	Neoplasms (Cancer) 01/2022 - 06/2003
29	Leukemia 01/2020 - 03/2002
24	Multiple Myeloma 10/2021 - 11/2002
12	Mitochondrial Diseases (Mitochondrial Disease) 07/2007 - 06/2003
9	Carcinogenesis 01/2022 - 05/2006
8	Colitis 01/2022 - 04/2013
8	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 07/2008
8	Colonic Neoplasms (Colon Cancer) 05/2014 - 06/2008
7	Inflammation (Inflammations) 01/2022 - 03/2009
7	Carcinoma (Carcinomatosis) 01/2018 - 05/2002
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 04/2004
6	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 05/2011 - 07/2004
5	Infections 01/2020 - 09/2009
5	Hematologic Neoplasms (Hematological Malignancy) 08/2019 - 07/2004
5	Hypoxia (Hypoxemia) 01/2019 - 08/2005
5	Obesity 06/2015 - 05/2006
4	Neoplasm Metastasis (Metastasis) 03/2022 - 04/2012
4	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2016
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2016 - 06/2008
4	Breast Neoplasms (Breast Cancer) 11/2015 - 11/2005
4	Myeloid Leukemia (Leukemia, Myelocytic) 12/2003 - 03/2002
3	Stomach Neoplasms (Stomach Cancer) 03/2019 - 05/2006
3	Insulin Resistance 01/2019 - 03/2010
3	Colitis-Associated Neoplasms 01/2018 - 05/2014
3	Body Weight (Weight, Body) 06/2015 - 05/2006
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/2011 - 01/2004
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022 - 01/2021
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 12/2017
2	Esophageal Neoplasms (Esophageal Cancer) 11/2019 - 09/2008

Drug/Important Bio-Agent (IBA)

22	Histone Deacetylase InhibitorsIBA 10/2021 - 07/2002
14	7-hydroxystaurosporine (UCN 01)IBA 05/2013 - 05/2002
12	Proteins (Proteins, Gene)FDA Link 11/2019 - 03/2002
12	Bortezomib (Velcade)FDA Link 01/2019 - 10/2003
10	Histone Deacetylases (Histone Deacetylase)IBA 10/2019 - 12/2003
10	alvocidib (flavopiridol)IBA 01/2018 - 03/2002
10	Vorinostat FDA Link 06/2013 - 12/2003
9	Pharmaceutical PreparationsIBA 01/2022 - 06/2005
9	Proteasome InhibitorsIBA 01/2019 - 10/2003
9	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 12/2008
9	CaspasesIBA 05/2014 - 03/2002
9	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2007 - 04/2003
8	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2004
8	Imatinib Mesylate (Gleevec)FDA Link 01/2019 - 11/2002
8	LigandsIBA 09/2015 - 12/2003
8	Butyric Acid (Butanoic Acid)IBA 04/2005 - 07/2002
7	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2012 - 11/2002
7	2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamideIBA 04/2012 - 11/2002
7	Cytochromes c (Cytochrome c)IBA 07/2007 - 05/2002
6	Peptides (Polypeptides)IBA 01/2022 - 04/2004
6	embelinIBA 01/2018 - 06/2009
6	Small Interfering RNA (siRNA)IBA 01/2018 - 08/2004
6	Phosphotransferases (Kinase)IBA 06/2013 - 11/2002
5	EnzymesIBA 01/2022 - 05/2014
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2013
5	Messenger RNA (mRNA)IBA 01/2021 - 08/2005
5	Apoptosis Regulatory ProteinsIBA 01/2020 - 02/2006
5	Interleukin-6 (Interleukin 6)IBA 01/2020 - 12/2004
5	PPAR gammaIBA 06/2009 - 06/2008
5	NF-kappa B (NF-kB)IBA 03/2009 - 09/2003
4	MicroRNAs (MicroRNA)IBA 08/2021 - 01/2013
4	CytokinesIBA 01/2020 - 12/2003
4	Checkpoint Kinase 1IBA 08/2012 - 12/2006
4	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 08/2012 - 04/2004
4	X-Linked Inhibitor of Apoptosis ProteinIBA 09/2009 - 06/2008
4	Caspase 3 (Caspase-3)IBA 09/2009 - 03/2005
4	Caspase 8 (Caspase-8)IBA 02/2005 - 05/2002
3	PanobinostatIBA 10/2021 - 04/2012
3	oxidized low density lipoproteinIBA 01/2019 - 10/2015
3	Dextran SulfateIBA 01/2018 - 04/2013
3	SolutionsIBA 01/2017 - 01/2010
3	Drug CombinationsIBA 01/2017 - 11/2005
3	LeptinIBA 06/2015 - 08/2009
3	ABT-737IBA 01/2014 - 01/2007
3	LipidsIBA 01/2013 - 12/2008
3	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2012 - 06/2004
3	AZD 6244IBA 04/2012 - 03/2008
3	entinostat (MS 275)IBA 05/2011 - 04/2004
3	Troglitazone (Rezulin)FDA Link 09/2008 - 06/2008
3	RoscovitineIBA 01/2007 - 04/2003
3	U 0126 (UO 126)IBA 12/2003 - 11/2002
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2003 - 07/2002
2	B7-H1 AntigenIBA 03/2022 - 09/2015
2	Immune Checkpoint InhibitorsIBA 03/2022 - 01/2022
2	ElafinIBA 01/2022 - 01/2019
2	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2022 - 01/2020
2	Ion Channels (Ion Channel)IBA 01/2022 - 12/2020
2	Dextrans (Dextran)FDA Link 01/2022 - 01/2020
2	Inhibitor of Apoptosis ProteinsIBA 10/2021 - 01/2019
2	HydrogelsIBA 09/2021 - 03/2014
2	Complement System Proteins (Complement)IBA 01/2021 - 01/2018
2	Long Noncoding RNAIBA 01/2021 - 01/2021
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2020
2	NeuropeptidesIBA 10/2020 - 06/2015
2	Dinoprostone (PGE2)FDA Link 10/2020 - 04/2013
2	venetoclaxIBA 01/2020 - 01/2018
2	N- (2- amino- 5- fluorobenzyl)- 4- (N- (pyridine- 3- acrylyl)aminomethyl)benzamideIBA 01/2020 - 10/2019

Therapy/Procedure

20	Therapeutics 03/2022 - 08/2003
7	Drug Therapy (Chemotherapy) 01/2020 - 06/2008
2	Immunotherapy 01/2022 - 01/2020
2	Hematopoietic Stem Cell Transplantation 06/2020 - 01/2017